Caricamento...
Bortezomib decreases the magnitude of a primary humoral immune response to transfused RBCs in a murine model
BACKGROUND: Few therapeutic options currently exist to prevent or to mitigate transfusion associated RBC alloimmunization. We hypothesized that bortezomib, a proteasome inhibitor currently being utilized for HLA alloantibody and ADAMTS13 autoantibody reduction, may be beneficial in a transfusion set...
Salvato in:
| Pubblicato in: | Transfusion |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5559200/ https://ncbi.nlm.nih.gov/pubmed/27734515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/trf.13864 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|